Avita Medical Announces Issuance of a New U.S. Patent for ReCell(R)
(firmenpresse) - NORTHRIDGE, CA and CAMBRIDGE, UNITED KINGDOM -- (Marketwired) -- 05/13/15 -- Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 9,029,140. The patent is directed to methods of making and using an epithelial cell suspension, part of the Company''s novel autologous skin regeneration therapy platform (ReCell®).
"This newly issued patent continues to strengthen and expand our overall patent coverage for ReCell. Moving forward, we are continuing to focus on the prosecution of additional patents that support our entire regenerative medicine franchise. This patent is a key milestone towards our commercialisation effort in the US," commented Adam Kelliher, CEO of Avita Medical.
The patent provides protection for methods for producing and using a transplantable cellular suspension of living tissue suitable for grafting to a patient. Avita has a robust intellectual property portfolio for its regenerative technology platform. ReCell®, ReGenerCell™ and ReNovaCell™ are protected by a family of patents and patent applications covering unique composition of final product, method of production, device and automation for methods and apparatus to generate epithelial suspension. Currently, pending worldwide patents and applications will expire in 2022-2034. Additional filings having a later expiration date will be made as Avita continues to invent in the regenerative medicine field.
Avita Medical () develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita''s patented and proprietary tissue-culture, collection and application technology provides innovative treatment solutions derived from a patient''s own skin. The Company''s lead product, ReCell®, is used in a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell is patented, CE-marked for Europe, TGA-registered in Australia, and CFDA-cleared in China. ReCell is not available for sale in the United States; in the United States, ReCell is an investigational device limited by federal law to investigational use. A Phase III FDA trial is in process.
Avita Medical Ltd
Adam Kelliher
Chief Executive Officer
Phone: +44 (0) 1763 269 772
Email:
Avita Medical Ltd
Tim Rooney
Chief Financial Officer
Phone: + 1 (818) 356-9400
Email:
Avita Medical Ltd
Gabriel Chiappini
Company Secretary
Phone:+61(0) 8 9474 7738
Email:
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 13.05.2015 - 04:00 Uhr
Sprache: Deutsch
News-ID 1358434
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
NORTHRIDGE, CA and CAMBRIDGE, UNITED KINGDOM
Phone:
Kategorie:
Drugs
Anmerkungen:
Diese Pressemitteilung wurde bisher 181 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Avita Medical Announces Issuance of a New U.S. Patent for ReCell(R)
"
steht unter der journalistisch-redaktionellen Verantwortung von
Avita Medical (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
